/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | LCTXLineage Cell Therape |
|---|---|
| Last close | $1.01close 2026-11-02 |
| Change % | +1.00%close 2026-11-02 |
| Market cap | $255Mclose 2026-11-02 |
| P/E | loss, no P/E |
| Revenue | $15M⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenues As ofFY ending 2025-12-31 Filing10-K · 0001193125-26-093992 · filed 2026-03-05 Open the filing on EDGAR → |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | 53.2%FY to 2025-12-31 |
| Net income | $-63533000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 FilingDEF 14A · 0001193125-26-191556 · filed 2026-04-29 Open the filing on EDGAR →Open the XBRL payload →CiteLineage Cell Therapeutics, Inc. (LCTX), us-gaap:NetIncomeLoss: -63,533,000 USD, fiscal year ended 2025-12-31. Form DEF 14A, accession 0001193125-26-191556, filed 2026-04-29. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0000876343/us-gaap/NetIncomeLoss.json |
| Net margin | -436.5%FY to 2025-12-31 |
| EPS (diluted) | $-0.28⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 Filing10-K · 0001193125-26-093992 · filed 2026-03-05 Open the filing on EDGAR →Open the XBRL payload →CiteLineage Cell Therapeutics, Inc. (LCTX), us-gaap:EarningsPerShareDiluted: -0.28 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001193125-26-093992, filed 2026-03-05. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0000876343/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 3FY to 2025-12-31 |
| Altman Z-ScoreUNVALIDATED | -4.03FY to 2025-12-31 |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | open now |